A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma by De Jesus-Acosta, Ana et al.
Cancer Chemother Pharmacol (2012) 69:415–424
DOI 10.1007/s00280-011-1704-y
123
ORIGINAL ARTICLE
A multicenter analysis of GTX chemotherapy in patients 
with locally advanced and metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta · George R. Oliver · Amanda Blackford · Katharine Kinsman · 
Edna I. Flores · Lalan S. Wilfong · Lei Zheng · Ross C. Donehower · David Cosgrove · 
Daniel Laheru · Dung T. Le · Ki Chung · Luis A. Diaz Jr. 
Received: 7 May 2011 / Accepted: 30 June 2011 / Published online: 29 July 2011
© The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Purpose Studies treating adenocarcinoma of the pancreas
with gemcitabine alone or in combination with a doublet
have demonstrated modest improvements in survival.
Recent reports have suggested that using the triple-drug
regimen FOLFIRINOX can substantially extend survival in
patients with metastatic disease. We were interested in
determining the clinical beneWt of another three-drug regi-
men of gemcitabine, docetaxel and capecitabine (GTX) in
patients with advanced pancreatic adenocarcinoma.
Patients and methods The cases of 154 patients, who
received treatment with GTX chemotherapy with histo-
logically conWrmed locally advanced or metastatic pancreatic
adenocarcinoma, were retrospectively reviewed. All demo-
graphic and clinical data were captured including prior
therapy, adverse events, treatment response and survival.
Results One hundred and seventeen metastatic and 37
locally advanced cases of adenocarcinoma of the pancreas
were reviewed. Partial responses were noted in 11% of
cases, and stable disease was observed in 62% of patients.
Responses signiWcantly correlated with toxicity (neutrope-
nia, ALT elevation and hospitalizations). Grade 3 or greater
hematologic and non-hematologic toxicities were noted in
41% and 9% of cases, respectively. Overall median sur-
vival was 11.6 months. Chemotherapy naïve patients with
metastatic and locally advanced disease achieved a median
survival of 11.3 and 25.0 months, respectively.
Conclusions We observe a substantial survival beneWt
with GTX chemotherapy in our cohort of patients with
advanced pancreatic cancer. These Wndings warrant further
investigation of this combination in this patient population.
Keywords Pancreatic cancer · Chemotherapy · Toxicity · 
Survival
Introduction
Since 1997, single-agent gemcitabine has been the standard
of care for advanced adenocarcinoma of the pancreas and
the barometer by which all new therapies are measured [1].
The median overall survival (mOS) of single gemcitabine is
approximately 6 months with a response rate of 10% in
chemotherapy naïve patients with metastatic disease [1]. At
least eight diVerent agents have been evaluated in phase
III studies in combination with gemcitabine, including
irinotecan, oxaliplatin, cisplatin, docetaxel, erlotinib,
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bevacizumab and cetuximab [2–12]. None have shown any
appreciable survival beneWt, except for gemcitabine and
erlotinib, which showed a small but signiWcant beneWt over
gemcitabine alone in patients with metastatic disease [8].
More recently, there has been increased interest, in the
use of triple-drug regimens in patients with advanced pan-
creatic cancer. The combination of biweekly administered
Xuorouracil, irinotecan and oxaliplatin in a regimen termed
FOLFIRINOX was studied in a phase III trial and was com-
pared with gemcitabine as Wrst-line treatment of metastatic
pancreatic adenocarcinoma (n = 342). The FOLFIRINOX
arm achieved a response rate of 31.6% and a mOS of
11.1 months [13].
Another three-drug regimen of interest is a combination
that relies on synergy between gemcitabine, capecitabine
and docetaxel (GTX), [14]. Optimized by Fine and col-
leagues, a prospective phase II study demonstrated
response rates of 21.9% and a mOS of 14.5 months (n = 43)
in advanced metastatic pancreatic adenocarcinoma [15].
Given the accessibility of GTX, many oncologists are now
using this regimen on a routine basis. However, the overall
beneWt of GTX regimen is not fully understood, especially
with the potential for greater toxicity.
Our institutions and others have noted improvements in
disease control and survival with GTX in patients with
advanced pancreatic adenocarcinoma. To evaluate the clin-
ical beneWt of this regimen, we compiled a large cohort of
patients with locally advanced and metastatic disease
treated at three diVerent institutions with the GTX regimen
and report the observations from this analysis.
Patients and methods
Patient eligibility
Patients with cytologically or histologically conWrmed adeno-
carcinoma of the pancreas who received GTX regimen at
Johns Hopkins Hospital, US Oncology—Dallas and Memorial
Sloan Kettering Comprehensive Cancer Center, were included
in this study. The retrospective review study was approved by
the IRB at each institution. Data were collected by chart
review of the patient’s medical records using a uniform data-
base format. All data were de-identiWed prior to analysis.
Treatment regimen
The treatment included gemcitabine, docetaxel and capecit-
abine (GTX) as proposed by Fine and colleagues: capecitabine
750 mg/m2/day orally divided into two doses, days 1–14;
intravenous (IV) gemcitabine 750 mg/m2 over 75 min on
days 4 and 11 and docetaxel 30 mg/m2 IV on days 4 and 11.
The cycles were repeated every 21 days. Chemotherapy
was continued until disease progression, unacceptable tox-
icity or patient intolerance.
Evaluation of tumor response
CT scans were reviewed in response to treatment after 2–3
cycles of therapy with GTX using the Response Evaluation
Criteria in Solid Tumors (RECIST). Complete response
(CR) was deWned as disappearance of all target lesions. Par-
tial response (PR) was deWned by at least 30% decrease in
the tumor load, estimated by the sum of the diameters of
target lesions. Progressive disease (PD) was deWned as an
increase of at least 20% in the sum of the diameters of tar-
get lesions. Stable disease (SD) was deWned as disease that
showed neither suYcient shrinkage nor increase to qualify
as either PR or PD.
Evaluation of toxicities
Any episodes of chemotherapy-associated hematologic
toxicities such as anemia, thrombocytopenia or leukopenia
were graded according to the National Cancer Institute
Common Toxicity Criteria 4.0 (NCI CTC v4.0). Non-
hematologic toxicities such as elevated AST and bilirubin
were also assessed. Non-hematological toxicities that
resulted in dose modiWcations were also collected. Toxici-
ties were assessed for all cycles of GTX delivered. The
number of hospitalizations during GTX treatment, regard-
less of cause, was recorded.
Statistical analysis
The overall study objective was to evaluate the eYcacy and
survival outcomes of a large unselected patient population
treated with GTX regimen. Statistical analysis was coordi-
nated by biostatisticians at Johns Hopkins Hospital. Char-
acteristics of patients were descriptively compared between
institutions using Wilcoxon rank sum tests or Fisher’s exact
tests. The frequencies of grade 3/4 toxicities and partial
responses, as measured using RECIST criteria, were com-
pared between disease stages, grades and other characteris-
tics with odds ratios that adjusted for patient age, sex, race
and institution.
Overall survival was calculated from the time of GTX
initiation until death. Patients who were alive at the time of
analysis were censored at the date of last observation. Sur-
vival curves were plotted by the Kaplan–Meier method and
compared using the log-rank test. Multivariate Cox propor-
tional hazard models were used to assess whether any clini-
cal predictors were independently associated with survival,
response or severe grades 3–4 toxicity. All P values are
based on two-tailed tests, and P = 0.05 was considered sta-
tistically signiWcant. The following variables were assessed:Cancer Chemother Pharmacol (2012) 69:415–424 417
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age, performance, number of previous lines of therapy and
number of comorbidities.
Results
Patient characteristics
Patient characteristics are summarized in Table 1. From
May 2003 to March 2010, a total of 154 patients received
GTX. Ninety-four percent of the treated patients received
treatment after 2006. At the time of GTX administration, 37
patients had radiographically conWrmed locally advanced
disease and 117 had conWrmed evidence of metastatic dis-
ease. (Twenty of the 37 patients with locally advanced dis-
ease had a prior history of radiation therapy.) Records were
obtained from three medical centers: Johns Hopkins Hospi-
tal, Memorial Sloan Kettering Comprehensive Cancer Cen-
ter and US Oncology—Dallas (Table S1).
The median age of the patients reviewed was 62 years.
The majority of patients was metastatic (77%) and had an
ECOG performance status (ECOG PS) of 1 (66%). GTX
was the Wrst regimen attempted for 51% of cases reviewed,
and the average number of cycles completed was 4.
Twenty-one percent of patients had prior surgery with cura-
tive intent prior to initiating GTX therapy. None of the
patients received GTX in the adjuvant setting.
Toxicities
Hematological and non-hematological toxicities were
assessed in all treated patients (n = 154) and are shown in
Table 2. No GTX-related deaths were noted. Hospitaliza-
tion data were available on 50% of patients, of which 33%
required at least one inpatient hospitalization while receiv-
ing GTX. Nine percent of patients experienced grade 3/4
non-hematological toxicity, and 41% experienced hemato-
logical toxicity. Grade 3/4 anemia, neutropenia and throm-
bocytopenia occurred in 12%, 34% and 13% of patients,
respectively (Table 2).
Table 1 Patients’ Characteristics
All patients
N =1 5 4
Age—median (range) 62 (37, 83)
Gender—no. (%)
Male 86 (56)
Female 68 (44)
Race—no. (%)
African American 12 (9)
Caucasian 120 (86)
Hispanic 3 (2)
Asian 5 (4)
Missing 14
Stage—no. (%)
Locally advanced 37 (24)
Metastatic 117 (76)
Grade—no. (%)
Well-diVerentiated 3 (2)
Moderately diVerentiated 31 (20)
Poorly diVerentiated 15 (10)
Unknown 105 (68)
ECOG—no. (%)
0 44 (29)
11 0 0  ( 6 6 )
27  ( 5 )
Missing 3
Number of comorbidities—median (range) 2 (0, 8)
Family history of cancer—no. (%)
Yes 115 (77)
No 35 (23)
Missing 4
Family history of pancreas cancer—no. (%)
Yes 7 (10)
No 65 (90)
Missing 82
Number of cycles—median (range) 4 (1, 40)
Number of metastatic sites—no. (%)
0 22 (29)
1 33 (43)
2 16 (21)
35  ( 7 )
Missing 78
Prior chemotherapy—no. (%)
No 79 (51)
Yes 75 (49)
Previous surgery—no. (%)
Yes 16 (21)
No 61 (79)
Missing 77
Table 1 continued
All patients
N =1 5 4
Line of GTX therapy—no. (%)
First 79 (51)
Second or greater 75 (49)
Ascites—no. (%)
Yes 25 (16)
No 129 (84)418 Cancer Chemother Pharmacol (2012) 69:415–424
123
Table 2 Frequency of toxicities, overall and by staging
LAPC locally advanced pancreatic cancer
All patients
N =1 5 4
LAPC
N =3 7
Mets, Wrst line
N =5 0
Mets, second + line
N =6 7
P value
Any grade 3/4 hematological toxicity—no. (%)
No 90 (59) 17 (47) 35 (70) 38 (58) 0.1
Yes 62 (41) 19 (53) 15 (30) 28 (42)
Missing 2 1 0 1
Thrombocytopenia—no. (%)
Grade 1/2 80 (68) 21 (68) 25 (66) 34 (69) 0.279
Grade 3/4 15 (13) 5 (16) 2 (5) 8 (16)
None 23 (19) 5 (16) 11 (29) 7 (14)
Missing 36 6 12 18
Neutropenia—no. (%)
Grade 1/2 41 (36) 13 (41) 10 (25) 18 (43) 0.185
Grade 3/4 39 (34) 13 (41) 13 (32) 13 (31)
None 34 (30) 6 (19) 17 (42) 11 (26)
Missing 40 5 10 25
Leucopenia—no. (%)
Grade 1/2 69 (57) 19 (59) 22 (54) 28 (60) 0.32
Grade 3/4 35 (29) 9 (28) 10 (24) 16 (34)
None 16 (13) 4 (12) 9 (22) 3 (6)
Missing 34 5 9 20
Anemia—no. (%)
Grade 1/2 129 (85) 30 (83) 46 (92) 53 (80) 0.125
Grade 3/4 19 (12) 5 (14) 2 (4) 12 (18)
None 4 (3) 1 (3) 2 (4) 1 (2)
Missing 2 1 0 1
Any grade 3/4 non-hematological 
toxicity—no. (%)
No 138 (91) 30 (86) 48 (96) 60 (91) 0.235
Yes 13 (9) 5 (14) 2 (4) 6 (9)
Missing 3 2 0 1
Elevated ALT—no. (%)
Grade 1/2 75 (50) 18 (51) 33 (66) 24 (36) 0.008
Grade 3/4 9 (6) 4 (11) 2 (4) 3 (5)
None 67 (44) 13 (37) 15 (30) 39 (59)
Missing 3 2 0 1
Bilirubin—no. (%)
Grade 1/2 35 (35) 8 (29) 11 (32) 16 (43) 0.132
Grade 3/4 5 (5) 1 (4) 0 (0) 4 (11)
None 59 (60) 19 (68) 23 (68) 17 (46)
Missing 55 9 16 30
Hospitalizations—no. (%)
None 51 (67) 20 (74) 17 (61) 14 (67) 0.617
1 or more 25 (33) 7 (26) 11 (39) 7 (33)
Missing 78 10 22 46Cancer Chemother Pharmacol (2012) 69:415–424 419
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Grade 3/4 toxicity from GTX was found to be indepen-
dent of treatment location (Table S3), stage, grade, ECOG
PS, prior surgery, ascites or hospitalization (Table S3). Any
prior chemotherapy minimally correlated with grade 3/4
toxicity (adjusted odds ratio (OR) 2.01, 95% CI 0.97–4.16,
P =0 . 0 5 7 ) .
Dose reductions and chemotherapy modiWcations were
evaluated in half of the patients (77/154). Hematological
complications (myelosuppression) resulted in dose reduc-
tion in 34% of the patients (26/77). Non-hematological
toxicities that resulted in dose modiWcations occurred in
30% of the patients (23/77). The reasons that resulted in
GTX dose modiWcations included one or more of the fol-
lowing: fatigue (n = 4) anasarca (n = 2), decreased perfor-
mance status (n = 2), diarrhea/mucositis (n = 12), intractable
nausea/vomiting (n = 3), hand and foot syndrome (n =2 )  o r
multiple procedures required (n =1 ) .
Response rates
One hundred and forty-six (95%) of the 154 cases were
evaluable for response using RECIST criteria [16]. Assess-
ments were performed after every 2–3 cycles of GTX che-
motherapy. Partial responses were seen in 11% (n = 16) of
patients. Stable disease was seen in 62% of cases (n = 91)
and progressive disease in 27% (n = 39). No complete
responses were observed. Response rates by extent of
disease and line of therapy are summarized in Table 3.
Elevated ALT, any neutropenia and hospitalization cor-
related strongly with achieving a partial response (adjusted
OR 3.57, 95% CI 0.92–13.8, P = 0.045, ALT elevation;
adjusted OR 5.10, 95% CI 0.9–28.91, P = 0.041, any neu-
tropenia; adjusted OR 5.37, 95% CI 1.09–26.51, P =0 . 0 3 2 ,
hospitalization). A borderline signiWcant correlation with
improved response was noted in metastatic patients who
received GTX as their Wrst-line therapy (adjusted OR 2.56,
95% CI 0.62–10.59, P = 0.055). Prior chemotherapy nega-
tively correlated with response (adjusted OR 0.16, 95% CI
0.03–0.83, P = 0.012). These Wndings are summarized in
Table 4.
Tumor marker analysis
Longitudinal CA19-9 values for the Wrst two cycles of ther-
apy were available for 86 cases. Patients that did not
express CA19-9 were excluded from the analysis. Seventy-
seven percent (n = 66) of patients demonstrated a measur-
able decline in CA19-9 after two cycles of therapy with
GTX. When GTX was used as Wrst-line therapy (n =4 8 ) ,  a
decline CA19-9 was observed in 91% of cases (Fig. 1). In
the second line or greater (n = 38), the CA19-9 response
was seen in 63% of cases.
There was no correlation between CA19-9 response,
objective radiographic response (Table 4) or survival when
measured as a continuous variable (Figure S1). Even when
CA19-9 responses were separated into groups using cutoVs
deWned by percent decline in CA19-9 levels or by line of
therapy, there was no correlation with overall survival
(Tables 5, S4).
Survival analysis
Chemotherapy naïve patients achieved a mOS of
11.6 months (n = 75) and a 1-year survival of 46% when
treated with GTX. Patients who received Wrst-line GTX
with metastatic and locally advanced disease achieved a
median survival of 11.3 and 25.0 months, respectively
Table 3 Response rates
LAPC locally advanced pancreatic cancer
All patients
N =1 5 4
LAPC
N =3 7
Metastatic
N =1 1 7
P value
RECIST—no. (%)
Partial response 16 (11) 4 (11) 12 (11) 0.012
Stable disease 91 (62) 28 (80) 63 (57)
Progressive disease 39 (27) 3 (9) 36 (32)
Missing 8 2 6
Fig. 1 Waterfall plot of the CA19-9 response in patients treated with
Wrst-line therapy with GTX
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Table 4 Predictors of response SD or PD
N =1 3 0
PR
N =1 6
Adjusted OR 95% CI P
Stage—no. (%)
Locally advanced 31 (24) 4 (25) 1.00 –
Metastatic 99 (76) 12 (75) 1.63 (0.4, 6.65) 0.484
Stage/GTX—no. (%)
Locally advanced 31 (24) 4 (25) 1.00 –
Mets, Wrst line 38 (29) 10 (62) 2.56 (0.62, 10.59) 0.055
Mets, second line 61 (47) 2 (12) 0.44 (0.06, 3.13)
Grade—no. (%)
Well or moderately 
diVerentiated
28 (22) 5 (31) 1.00 –
Poorly diVerentiated 
or unknown
102 (78) 11 (69) 0.51 (0.15, 1.77) 0.3
ECOG—no. (%)
0 37 (29) 6 (38) 1.00 –
1+ 91 (71) 10 (62) 0.56 (0.17, 1.83) 0.341
Prior chemotherapy—no. (%)
No 62 (48) 14 (88) 1.00 –
Yes 68 (52) 2 (12) 0.16 (0.03, 0.83) 0.012
Previous surgery—no. (%)
Yes 15 (25) 1 (8) 1.00 –
No 46 (75) 11 (92) 1.44 (0.14, 15.03) 0.756
Ascites—no. (%)
Yes 21 (16) 1 (6) 1.00 –
No 109 (84) 15 (94) 5.83 (0.59, 57.55) 0.074
Any grade 3/4 hematological 
toxicity—no. (%)
No 77 (60) 8 (50) 1.00 –
Yes 51 (40) 8 (50) 1.27 (0.41, 3.95) 0.682
Any grade 3/4 non-hematological 
toxicity—no. (%)
No 116 (91) 16 (100) 1.00 –
Yes 11 (9) 0 (0) 0.00 (0, Inf) 0.103
Thrombocytopenia—no. (%)
None 19 (20) 4 (27) 1.00 –
Any 77 (80) 11 (73) 0.73 (0.18, 2.96) 0.667
Neutropenia—no. (%)
None 29 (31) 2 (14) 1.00 –
Any 65 (69) 12 (86) 5.10 (0.9, 28.91) 0.041
Leucopenia—no. (%)
None 14 (14) 1 (6) 1.00 –
Any 84 (86) 15 (94) 3.53 (0.39, 31.83) 0.203
Anemia—no. (%)
None 4 (3) 0 (0) 1.00 –
Any 124 (97) 16 (100) Inf (0, Inf) 0.43
Elevated ALT—no. (%)
None 58 (46) 4 (25) 1.00 –
Any 69 (54) 12 (75) 3.57 (0.92, 13.8) 0.045Cancer Chemother Pharmacol (2012) 69:415–424 421
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(Fig. 2). In the Wrst-line setting, only ECOG PS correlated
with improved survival (adjusted HR 2.57, 95% CI 1.03–
6.41, P = 0.043) as shown in Table 5.
When GTX was used as second line or greater (n = 79),
the mOS was 5.7 months and 1-year survival was 32%
(Table S4). In patients with locally advanced disease, the
mOS was 16.2 and 5.7 months in metastatic patients.
Prior surgery with curative intent (adjusted HR 529.1, 95%
CI 3.52–79,433.25, P = 0.014) strongly correlated with
improved survival. In the second line setting, experiencing
any grade 3/4 toxicity was a negative factor for survival
(adjusted HR 0.47, 95% CI 0.25–0.9, P =0 . 0 2 2 ) .
In the Wrst and second lines of therapy with GTX, there
was a marked improvement in survival in patients who
demonstrated a RECIST-based partial response (Table 5,
Table S4).
Discussion
Advanced pancreatic adenocarcinoma is a genetically com-
plex disease that is uniformly lethal with annual incidence
approaching its yearly mortality [17]. Much like other solid
tumors, disease progression is most dependent on time as
measured by the sequential accumulation of somatic muta-
tions [18, 19]. Despite improvements in the treatment of
other solid tumors, the use of combination chemotherapy or
the introduction of novel targeted molecules has minimal
objective beneWt.
The failure of several phase III trials examining doublet
chemotherapy in metastatic pancreatic adenocarcinoma
prompted us to examine our use of the triplet, GTX. Origi-
nally reported by Fine and colleagues, this regimen com-
bines relatively low doses of gemcitabine and docetaxel in
synergy to augment the performance of capecitabine. GTX
was optimized in pancreatic cancer cell lines, where cape-
citabine was sequenced 72–96 h before docetaxel and gem-
citabine to achieve maximal tumor kill [14]. Initial human
studies demonstrated prolonged survivals in good perfor-
mance status patients [15].
Our data are consistent with the previous reports using
GTX and other triple-drug regimens and beg the question
whether more chemotherapy is better? A series of studies
Table 4 continued SD or PD
N =1 3 0
PR
N =1 6
Adjusted OR 95% CI P
Bilirubin—no. (%)
None 45 (56) 11 (92) 1.00 –
Any 36 (44) 1 (8) 0.26 (0.02, 2.68) 0.208
Hospitalizations—no. (%)
None 42 (70) 6 (50) 1.00 –
1 or more 18 (30) 6 (50) 5.37 (1.09, 26.51) 0.032
Change in CA19 from baseline –
<25% 34 (36) 4 (29) 1.00 –
25–50% 24 (25) 3 (21) 1.81 (0.29, 11.3)
50–75% 18 (19) 1 (7) 0.46 (0.04, 5.53)
>75% 19 (20) 6 (43) 4.79 (0.88, 25.9) 0.112 Adjusted odds ratios for the 
likelihood of achieving a PR
Fig. 2 Kaplan–Meier estimates of patients treated with GTX as
Wrst-line therapy with a locally advanced and b metastatic pancreatic
cancer
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by Reni et al. utilizing four agents: cisplatin, epirubicin,
Xuorouracil and gemcitabine (PEFG) has been reported and
showed a signiWcant improvement in radiographic response
that was accompanied by increases in grades 3–4 neutropenia
and thrombocytopenia [20,  21]. Whether adding more
agents is the best approach remains to be seen, but the primary
concern for future adoption of any multiagent regimens
appears to be the frequency of signiWcant toxicity.
Table 5 Estimates of OS (time from start of GTX therapy to death) for patients who received their Wrst line of GTX
Values are OS (95% CI)
LAPC locally advanced pancreatic cancer
N Median OS 
(months)
1 year OS HR 95% CI P
All patients 79 11.6 46 (34, 62)
All patients, by staging
LAPC 29 25.03 56 (37, 84) 1.00 –
Mets 50 11.3 42 (28, 62) 1.37 (0.6, 3.13) 0.461
Grade
Well or moderately diVerentiated 15 21.93 60 (36, 100) 1.00 –
Poorly diVerentiated or unknown 64 11.3 43 (30, 61) 1.29 (0.51, 3.27) 0.595
ECOG
0 28 23.23 64 (44, 94) 1.00 –
1+ 50 9.9 38 (25, 58) 2.57 (1.03, 6.41) 0.043
Prior surgery
Yes 4 14.27 100 (100, 100) 1.00 –
No 44 9.9 42 (26, 69) 0.84 (0.08, 9.29) 0.886
Hospitalizations
None 32 14.27 51 (31, 83) 1.00 –
1 or more 15 11.3 44 (21, 89) 0.84 (0.22, 3.19) 0.8
Any grade 3/4 toxicity
No 47 11.7 48 (33, 69) 1.00 –
Yes 31 9.9 41 (24, 70) 1.03 (0.5, 2.13) 0.928
Family history of cancer
No 19 8.87 10 (2, 61) 1.00 –
Yes 57 14.27 59 (46, 76) 0.61 (0.27, 1.35) 0.221
Comorbidities
None 10 14.27 86 (63, 100) 1.00 –
1 or more 38 9.5 31 (15, 65) 2.74 (0.45, 16.56) 0.273
Neutropenia
No 22 9.5 47 (26, 85) 1.00 –
Yes 42 12.13 52 (36, 74) 1.00 (0.39, 2.52) 0.994
Elevated ALT
No 24 8.07 32 ((15, 69) 1.00 –
Yes 53 13.3 52 (38, 71) 0.73 (0.34, 1.56) 0.42
Change in CA19 from baseline
<25% 20 7.97 39 (19, 76) 1.00 –
25–50% 20 12.13 51 (31, 84) 0.76 (0.26, 2.22) 0.582
50–75% 13 9.03 25 (8, 83) 1.19 (0.38, 3.73)
>75% 12 13.3 62 (38, 100) 0.56 (0.18, 1.76)
RECIST-based response
Partial response 14 21.93 65 (42, 100) 1.00 –
Stable disease 50 12.13 51 (35, 73) 2.03 (0.7, 5.93)
Progressive disease 12 7.93 10 (2, 65) 6.32 (1.74, 22.9) 0.017
Missing 3 4.6 33 (7, 100)Cancer Chemother Pharmacol (2012) 69:415–424 423
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Interestingly, in our cohort, developing toxicities from
GTX (any neutropenia, elevated ALT and hospitalizations)
were markers for objective radiographic responses. This
has been noted with both targeted and conventional chemo-
therapy regimens where systemic toxicity correlated with
clinical response (e.g., skin rash to EGFR inhibitors) and
suggests that germ line factors may dictate the sensitivity to
this and other such regimens [22].
Perhaps, the most surprising Wnding is the 25-month
survival seen in the Wrst-line setting in patients with unre-
sectable locally advanced disease, which exceeds the
median survival in patients undergoing surgical resection
[23, 24]. It is also more than twice the survival demon-
strated in those patients with metastatic disease receiving
Wrst-line GTX. Given these Wndings, it is interesting to
speculate that locally advanced and metastatic pancreatic
cancer may represent two separate disease entities that may
in part be diVerentiated by DPC4 expression [25]. An
alternative explanation is that the locally advanced cases
may represent a less genetically complex disease state,
that is, therefore more susceptible to multiagent chemo-
therapy [19].
We were also surprised to Wnd the CA19-9 response did
not correlate with survival or response in this cohort of
patients, even when examined as a continuous or discrete
variable. While more than 75% of the cases reviewed dem-
onstrate CA19-9 decline after two cycles, this did not corre-
spond with a decline in tumor burden. Nonetheless, a
Xuctuation in the CA19-9 level does suggest that chemo-
therapy was reaching the tumor and altering CA19-9 pro-
duction by tumor or adjacent cells.
In summary, GTX appears to be an active three-drug
regimen in advanced adenocarcinoma of the pancreas, in
particular, in those patients with therapy-associated toxic-
ity. These Wndings further support future clinical investiga-
tion of multiagent regimens, such as GTX, in the treatment
of pancreatic cancer.
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